ObjectivesTo systematically review the efficacy and safety of esomeprazole versus omeprazole in the treatment of acute non-variceal upper gastrointestinal bleeding (ANVUGIB).MethodsPubMed, EMbase, The Cochrane Library, CNKI, WanFang Data and VIP databases were electronically searched to collect the randomized controlled trials (RCTs) about the efficacy and safety of esomeprazole versus omeprazole in the treatment of ANVUGIB from inception to January, 2019. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies, then, meta-analysis was performed by using RevMan 5.3 software.ResultsA total of 17 RCTs involving 2 086 patients were included. The results of meta-analysis showed that, the total effective rate of esomeprazole group was higher than omeprazole group (RR=1.09, 95%CI 1.04 to 1.14, P=0.000 6), the incidence of adverse reactions was lower than omeprazole group (OR=0.27, 95%CI 0.18 to 0.40, P<0.000 01), the average hemostasis time was shorter than omeprazole group (MD=?0.64, 95%CI ?0.94 to ?0.34, P<0.0001), and the difference were statistically significant.ConclusionsCurrent evidence shows that in the treatment of ANVUGIB, esomeprazole has rapid hemostasis, significant effect and fewer adverse reactions, which is worthy of wide application and promotion. Due to limited quality and quantity of the included studies, more high-quality studies are required to verify the above conclusions.
ObjectivesTo systematically review the association between body mass index (BMI) and mortality of chronic obstructive pulmonary disease (COPD).MethodsPubMed, EMbase, The Cochrane Library, CNKI, WanFang Data and VIP databases were electronically searched to collect cohort studies on the association between BMI and mortality of COPD from inception to February, 2019. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Meta-analysis was then performed using RevMan 5.3 software.ResultsA total of 14 cohort studies involving 494 060 COPD patients were included. The results of meta-analysis showed that, compared with patients having a normal weight, underweight individuals were associated with higher mortality (RR=1.40, 95%CI 1.15 to 1.71, P=0.000 8), whereas overweight (RR=0.65, 95%CI 0.54 to 0.79, P<0.000 1) and obese (RR=0.37, 95%CI 0.20 to 0.67, P=0.001) patients were associated with lower mortality.ConclusionsCurrent evidence shows that underweight is associated with a higher risk of all-cause mortality among patients with COPD, whereas overweight and obese are associated with lower risk of all-cause mortality in these patients. Due to limited quality and quantity of the included studies, more high quality studies are required to verify above conclusions.
目的 研究無創通氣(NIPPV)治療對腎移植術后巨細胞病毒(CMV)肺炎患者的療效。方法 1998年1月~2005年12月間入住中山大學附屬第一醫院內科重癥監護病房(MICU)的78例腎移植術后CMV肺炎患者，根據是否接受無創通氣治療而分為非NIPPV組和NIPPV組，比較兩組患者在接受有創機械通氣比例、病死率、住院時間及并發癥等方面的差異。對52例NIPPV組患者，比較無創通氣治療前后生命體征及血氣分析指標的變化。結果 NIPPV組與非NIPPV組相比，接受有創機械通氣比例(30.8％ 比80.8％)、醫院獲得性肺炎發生率（32.7％ 比61.5％)及病死率(30.8％ 比57.7％)較低，兩組比較均有顯著性差異(P均lt;0.05)；而住院時間、氣壓傷發生率無顯著差異。NIPPV組患者無創通氣治療后患者呼吸頻率有所減慢，動脈血pH值逐漸降低，PaCO2水平緩慢上升，PaO2、PaO2 ／FiO2及SaO2明顯升高，兩組比較均有顯著差異(P均lt;0.05)。而無創通氣治療前后心率、血壓的變化則無明顯規律。結論 NIPPV治療能夠改善腎移植術后CMV肺炎患者的低氧血癥，緩解呼吸窘迫癥狀，降低有創機械通氣治療比例及醫院獲得性肺炎的發生率，從而降低病死率。用無創通氣治療巨細胞病毒肺炎值得在臨床上推廣使用。